MedicineEurope PMC
Ranked by formulaVerdict: NotableA self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE study
The trade-offs between regulatory preferences, trial success probability, and patient exclusion by eligibility criteria in randomised controlled trials (RCTs) of biologics for severe asthma remain poorly…
Key numbers
- 95% CI 0.47-0.60
- 95% CI 0.39-0.48
VerdictWorth a reader's time today.
Abstract
Background The trade-offs between regulatory preferences, trial success probability, and patient exclusion by eligibility criteria in randomised controlled trials (RCTs) of biologics for severe asthma remain poorly understood. We assessed biologic effectiveness and effect modification by nine RCT-derived criteria in a large real-world cohort of subspecialist-treated patients with severe asthma. Methods CHRONICLE was a multicentre, prospective, noninterventional cohort of adults (aged ≥18 years) in the United States of America with severe asthma (ClinicalTrials.gov identifier NCT03373045). We performed a meta-analysis of six RCTs to estimate pooled rate ratios for United States Food and Drug Administration approved biologics and compared with incidence rate ratios (IRRs) from a self-controlled case-series using CHRONICLE data, analysing severe asthma exacerbation rates during biologic-exposed and unexposed periods. Subgroup analyses examined between-group comparisons (inclusion versus exclusion) across nine RCT-based criteria. Findings Biologics reduced exacerbation rates in both RCT meta-analysis (rate ratio 0.53, 95% CI 0.47-0.60) and real-world self-controlled case-series of 480 patients from 85 sites (enrolled between 28 February 2018 and 28 October 2024) (IRR 0.43, 95% CI 0.39-0.48). Significant effect modification (ratio of ratios, ratio of IRR (95% CI), with exclusion as the reference) was observed for smoking history (0.50, 0.38-0.66), exacerbation history (0.49, 0.36-0.65), exhaled nitric oxide fraction (0.63, 0.42-0.92), and blood eosinophil count (0.65, 0.51-0.82). No significant differences were observed for COPD, bronchiectasis, or forced expiratory volume in 1 s based criteria, which excluded the most patients in the cohort. Interpretation Criteria based on elevated type 2 biomarkers, minimal smoking, and exacerbation history enrich trial populations likely to benefit from biologics. Spirometry-based exclusions appear to have limited influence on treatment response, and there is a risk that they unduly restrict generalisability.
The editor's rubric
- Leverage3 / 5
- A method or resource many groups across the field will adopt within a year.
- Magnitude2 / 5
- Solid incremental gain on a meaningful problem.
- Evidence5 / 5
- Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.
- Novelty2 / 5
- A new combination of known ideas.
- Trajectory2 / 5
- Some room to improve with obvious engineering.
- Stakes2 / 5
- Benefits a professional community (practitioners, clinicians, engineers).
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: breadth (many tasks); novelty (open problem); design (randomized, registered, multicenter); verification (confidence interval); stakes (prevention or cure). Red flags: weak evidence (case report).
How the score was computed
Desks place stronger verdicts first, then use this score to order work within the same verdict.
- Merit
- 6.1 / 10
- Adjusted merit
- 5.0 / 10
- Attention
- 4%
- Freshness
- 80%
- Citations1 (reference 20, via openalex, Oct 25, 2026, 06:17 UTC)